

ENA (Extractable Nuclear Antigens) are proteins found in the nucleus of cells that can trigger an autoimmune response. The Extractable Nuclear Antigens (ENA) Profile, Quantitative helps diagnose various autoimmune diseases, including systemic lupus erythematosus (SLE), Sjogren's syndrome, rheumatoid arthritis (RA), scleroderma, and other mixed connective tissue disorders.
This test confirms the presence of autoantibodies that target specific nuclear antigens. It looks at a set of antigens, including those related to extractable nuclear antigens (ENA), which are key indicators of autoimmune diseases. By identifying certain antigens linked to different autoimmune disorders, the Extractable Nuclear Antigens (ENA) Profile, Quantitative helps doctors understand and classify the type of autoimmune response happening in an individual’s body.
The Extractable Nuclear Antigens (ENA) Profile, Quantitative is typically suggested when a doctor suspects an autoimmune disorder due to symptoms such as joint pain, fatigue, skin rashes, light sensitivity, or inflammation. Also, it may be advised if there are risk factors, such as a family history of autoimmune diseases. Additionally, it can be done if other laboratory tests or clinical findings suggest an autoimmune cause for the symptoms. The Extractable Nuclear Antigens (ENA) Profile, Quantitative is also useful for monitoring disease activity and treatment response in patients already diagnosed with autoimmune diseases. Overall, recommending Extractable Nuclear Antigens (ENA) Profile, Quantitative is based on the patient’s clinical presentation, medical history, and the doctor’s discretion in ruling out other potential causes of symptoms.
No special preparation is required for this test. Inform the doctor about any medications or supplements being taken, as they may affect the test results. Additionally, telling a detailed medical history and discussing symptoms can help the doctor correlate the clinical and laboratory findings.
The test results may vary depending on various factors like age, medical history, and certain risk factors, among others. Abnormal test results require an expert interpretation. Therefore, never self-medicate at home based solely on these results. Always consult a doctor to understand the test results correctly. The insights from this test help the doctor tailor appropriate treatment plans.
Please note: This is an outsourced test. The sample for this test is collected by TATA 1MG and processed at a NABL accredited partnered lab.
The Extractable Nuclear Antigens (ENA) Profile, Quantitative measures various autoantibodies that target extractable nuclear antigens, which helps in identifying specific autoimmune diseases. This test includes a panel that checks for several antibodies, such as the SCL-70 antibody, which is associated with systemic sclerosis, and Anti-SS-A and Anti-SS-B antibodies, which are linked to Sjögren's syndrome and systemic lupus erythematosus (SLE). It also tests for the Jo-1 antibody, related to polymyositis; the Sm antibody, which is connected to SLE; the Centromere antibody for CREST syndrome; and U1-SnRNP for mixed connective tissue disease. Together, these tests offer a comprehensive evaluation of autoimmune activity. They enable clinicians to understand immune mechanisms and tailor appropriate therapeutic interventions.
The Scl-70 Antibody test detects anti-topoisomerase I antibodies in the blood. These autoantibodies target topoisomerase I, an enzyme essential for unwinding DNA during cell replication. Their presence indicates an autoimmune reaction, where the immune system mistakenly attacks the body’s own tissues.
SCL-70 antibodies are found in about 40% of patients with progressive systemic sclerosis (PSS). A positive result suggests a higher likelihood of systemic sclerosis, particularly the diffuse cutaneous type, which is more often associated with lung and internal organ involvement. However, not all patients with systemic sclerosis test positive for SCL-70 antibodies, and in some cases, these antibodies may also appear in other connective tissue diseases. A negative result does not rule out systemic sclerosis but makes the diagnosis less likely. Results must always be interpreted in combination with symptoms, physical findings, and other laboratory and imaging studies, not standalone.
Know more about Scl-70 Antibody
The SSA - RO (Soluble Substance A)- IgG antibody is a blood test that detects IgG autoantibodies that react against SS-A (Ro) antigens. A positive result suggests an autoimmune response and helps confirm disorders such as lupus or Sjögren’s syndrome.
Know more about SSA - RO (Soluble Substance A)- IgG antibody
The Extractable Nuclear Antigens (ENA) Profile, Quantitative is done:
- To identify and distinguish between autoimmune diseases like lupus, Sjögren’s syndrome, scleroderma, and polymyositis.
- To confirm a diagnosis in individuals showing symptoms like joint pain, skin changes, dry eyes or mouth, or muscle weakness.
- To assess the risk in individuals with a family history of autoimmune diseases.
- To help plan better treatment for autoimmune conditions and make interventions more effective.
- To track how autoimmune disorders are progressing and see how well treatments are working over time.
- No special preparation is required.

































